FOLFIRI plus cetuximab—preferred first-line treatment for mCRC

被引：0
|
作者：
Lisa Hutchinson
机构：
来源：
Nature Reviews Clinical Oncology | 2014年 / 11卷 / 10期
关键词：
D O I：
10.1038/nrclinonc.2014.141
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：560 / 560
相关论文
共 50 条
  • [31] Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for mCRC - First BEATrial
    Georgoulias, V.
    Berry, S.
    Di Bartolomeo, M.
    Kretzschmar, A.
    Michael, M.
    Rivera, F.
    Mazier, M. A.
    Lutiger, B.
    VanCutsem, E.
    Cunningham, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 168 - 169
  • [32] Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial
    Kretzschmar, A.
    Van Cutsem, E.
    Michael, M.
    Rivera, F.
    Berry, S.
    DiBartolomeo, M.
    Mazier, M.
    Lutiger, B.
    Cunningham, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] A randomized, open-label cecog phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab and FOLFIRI plus cetuximab as first-line therapy in metastatic colorectal cancer (MCRC)
    Ciuleanu, T.
    Scheithauer, W.
    Kurteva, G.
    Ocvirk, J.
    Koza, I
    Papamichael, D.
    Vrbanec, D.
    Brodowicz, T.
    Beslija, S.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [34] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
    Heinemann, Volker
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmueller, Christian
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Hielscher, Joerg
    Scholz, Michael
    Mueller, Sebastian
    Link, Hartmut
    Niederle, Norbert
    Rost, Andreas
    Hoeffkes, Heinz-Gert
    Moehler, Markus
    Lindig, Reinhard U.
    Modest, Dominik P.
    Rossius, Lisa
    Kirchner, Thomas
    Jung, Andreas
    Stintzing, Sebastian
    LANCET ONCOLOGY, 2014, 15 (10): : 1065 - 1075
  • [35] Analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC)
    Stintzing, S.
    Jung, A.
    Vehling-Kaiser, U.
    Stauch, M.
    Hass, H.
    Dietzfelbinger, H.
    von Weikersthal, Fischer L.
    Moosmann, N.
    Kirchner, T.
    Heinemann, V
    ONKOLOGIE, 2010, 33 : 226 - 226
  • [36] Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Peeters, M.
    Raoul, J.-L.
    Van Laethem, J.-L.
    Rougier, P.
    Brezault, C.
    Husseini, F.
    Cals, L.
    Zubel, A.
    Vedovato, J.-C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 188 - 188
  • [37] Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)
    Cervantes, A.
    Macarulla, T.
    Martinelli, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Stroh, C.
    Nippgen, J.
    Baselga, J.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] First-line therapy with cetuximab followed by cetuximab plus folfiri in patients with metastatic colorectal cancer: KRAS mutation status correlates with clinical outcome
    Martinelli, E.
    Macarulia, T.
    Vega-Villegas, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Ramos, F.
    Rivera, F.
    Stroh, C.
    Nippgen, J.
    Cervantes, A.
    Baselga, J.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [39] Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study
    Pinto, C.
    Orlandi, A.
    Normanno, N.
    Maiello, E.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Pini, S.
    Bergamo, F.
    Tonini, G.
    Avallone, A.
    Latiano, T. P.
    Rosati, G.
    Pazzola, A.
    Ballestrero, A.
    Zaniboni, A.
    Roselli, M.
    Tamberi, S.
    Barone, C. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1390 - S1390
  • [40] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
12345